BriaCell Therapeutics Prices $4.7M Offering at Discount, Shares Diluted
BCTX sits 24% above its 52-week low of $2.98.
Summary
BriaCell Therapeutics priced a best-efforts offering of 1.45 million common shares at $3.25 each, aiming to raise approximately $4.7 million. This offering, priced at a discount to the current market price, is highly dilutive, representing about 17.8% of the company's market capitalization. The capital raise is crucial for working capital and general corporate purposes, especially given the company's previous 10-Q filing on March 10th, which included a going concern warning and substantial net losses. The offering is expected to close on June 2nd.
At the time of this announcement, BCTX was trading at $3.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $2.98 to $36.90. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.